Special Issue

Endoscopic Diagnosis and Treatment in Hepato-Pancreato-Biliary (HPB) Cancers

Message from the Guest Editors

The endoscopic diagnosis and treatment of hepatopancreato-biliary cancers have seen significant progress in recent years. These procedures are primarily performed using endoscopic retrograde cholangiopancreatography (ERCP) and interventional endoscopic ultrasonography (EUS). The ERCP technique has a long history but is continuing to evolve with advancements in devices. Interventional EUS serves both diagnostic purposes, such as EUS-guided fineneedle aspiration (FNA) and contrast-enhanced EUS, and therapeutic purposes, including EUS-guided drainage. The development of interventional EUS has significantly transformed strategies for the endoscopic diagnosis and treatment of hepato-pancreato-biliary cancers. It is crucial to evaluate and summarize the current state of endoscopic diagnosis and treatment in hepatopancreatic and biliary cancers and to identify future challenges. This Special Issue will highlight the latest advances in these areas, assessing the usefulness of new techniques and equipment developments, as well as the current role of longstanding methods.

Guest Editors

Dr. Mamoru Takenaka

Department of Gastroenterology and Hepatology, Kinki University, Osaka 589-8511, Japan

Prof. Dr. Hirofumi Kogure

Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo 173-8610, Japan

Deadline for manuscript submissions

closed (15 July 2025)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/216019

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

